Back to Authors

Santoro, Armando

https://orcid.org/0000-0003-1709-9492

A5100766578 | I4210163047

Mayo Clinic

IRCCS Humanitas Research Hospital

Citations 21

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma

Blood | January 10, 2017 | Volume: 129 | Issue: 10 | Pages: 1380-1388

10.1182/blood-2016-09-738385 | PMID 28073785

Key Points HSCT after PD-1 blockade is feasible, although may be associated with increased early immune toxicity. PD-1 blockade may cause persistent depletion of PD1+ T cells and alterations in T-cell differentiation impacting subsequent treatment.